The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).
 
Dylan J. Martini
No Relationships to Disclose
 
Yuan Liu
No Relationships to Disclose
 
Colleen Margaret Lewis
No Relationships to Disclose
 
Julie M. Shabto
No Relationships to Disclose
 
Mehmet Akce
No Relationships to Disclose
 
Haydn Kissick
No Relationships to Disclose
 
Bradley Curtis Carthon
Consulting or Advisory Role - Astellas Medivation; Blue Earth Diagnostics; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Walid Labib Shaib
Research Funding - ArQule (Inst); Lilly (Inst)
 
Olatunji B. Alese
No Relationships to Disclose
 
Rathi Narayana Pillai
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Natera
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Clovis Oncology; Genentech/Roche; Novartis; Takeda
 
Conor Ernst Steuer
No Relationships to Disclose
 
Christina Wu
Honoraria - BioTheranostics
Research Funding - Amgen; Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Vaccinex (Inst)
 
David H. Lawson
No Relationships to Disclose
 
Ragini Reiney Kudchadkar
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Novartis
Research Funding - Merck
 
Bassel F. El-Rayes
Honoraria - Bayer; Lexicon; RTI Health Solutions
Consulting or Advisory Role - Bayer; BTG; Loxo; Merrimack; RTI Health Solutions
Speakers' Bureau - Bristol-Myers Squibb; Lexicon
Research Funding - AVEO (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Cleave Biosciences (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); ICON Clinical Research (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); PPD (Inst); Taiho Pharmaceutical (Inst)
 
Viraj A. Master
No Relationships to Disclose
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Merck; Takeda
Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer
 
Taofeek Kunle Owonikoko
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Eisai; Eisai; G1 Therapeutics; Lilly; MedImmune; Novartis; Sandoz; Seagen; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); G1 Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst)
 
R. Donald Harvey
No Relationships to Disclose
 
Mehmet Asim Bilen
Consulting or Advisory Role - Exelixis; Sanofi
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Nektar (Inst); Peleton (Inst); Pfizer (Inst); Tricon Pharmaceuticals (Inst)